Bharathisha BS, Prasanna Sagar, SB Puranik, Swamy Sreenivasa, and Madhu Chakrapani Rao
The incidence and spectrum of local as well as systemic fungal infections have increased dramatically over the past two decades. Various factors which predispose patient to invasive fungal infections are advances in medical technology, use of invasive monitoring devices, mechanical ventilation, parenteral nutrition, broad spectrum antimicrobial agents, intensive cancer chemotherapies, corticosteroid and other immunosuppressive. Traditionally, many invasive fungal infections were associated with a poor prognosis, because effective therapeutic options were limited. The recent development of new antifungal agents has significantly contributed to the successful treatment of fungal diseases. These drugs offer novel mechanisms of action and expanded spectrums of activity over traditional treatment options. However, with these new agents comes the need for increased awareness of the potential interactions and toxicities associated with these drugs. Therefore, an understanding of the pharmacokinetic and pharmacodynamic properties of the classes of antifungal compounds is vital for the effective management of invasive fungal infections. This review provides a summary of the pharmacologic principles involved in treatment of fungal diseases.